PI
KPTI icon

Putnam Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Putnam Investments’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,854
Closed -$265K – 1173
2023
Q2 		$265K Buy
9,854
+1,803
+22% +$77.7K ﹤0.01% 1103
2023
Q1 		$470K Sell
8,051
-8,124
-50% -$401K ﹤0.01% 953
2022
Q4 		$825K Buy
+16,175
New +$1.12M ﹤0.01% 861

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Putnam Investments's KPTI Position: Q3 2023 in Review

Putnam Investments sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 9,854 shares — an estimated $265K sold.

Putnam Investments first reported a position in KPTI in Q4 2022 and held it in 3 quarters. The position peaked at $825K in Q4 2022. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

  • Putnam Investments reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Putnam Investments sold 9,854 Karyopharm Therapeutics shares in Q3 2023, an estimated $265K.
  • Putnam Investments first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 3 quarters.
  • Putnam Investments's Karyopharm Therapeutics position peaked at $825K in Q4 2022.
  • 118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Putnam Investments's 13F filing for Q3 2023, filed 14 Nov 2023.